These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7842530)

  • 41. Elevated circulating T cell subsets and cytokines expression in patients with rheumatoid arthritis.
    Zhou H; Hu B; Zhaopeng Z; Liu J; Zhong Q; Fan Y; Li L
    Clin Rheumatol; 2019 Jul; 38(7):1831-1839. PubMed ID: 30809737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of combined therapy of rheumatoid arthritis on the acute phase reactants.
    Rexhepi S; Rexhepi M; Sahatçiu-Meka V; Pllana E; Dragusha G; Gashi M; Rexhepi B
    Reumatizam; 2009; 56(2):77-80. PubMed ID: 20429264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Microalbuminuria in patients with rheumatoid arthritis.
    Pedersen LM; Nordin H; Svensson B; Bliddal H
    Ann Rheum Dis; 1995 Mar; 54(3):189-92. PubMed ID: 7748016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.
    McCarey DW; McInnes IB; Madhok R; Hampson R; Scherbakov O; Ford I; Capell HA; Sattar N
    Lancet; 2004 Jun; 363(9426):2015-21. PubMed ID: 15207950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures.
    Beckham JC; Caldwell DS; Peterson BL; Pippen AM; Currie MS; Keefe FJ; Weinberg JB
    J Clin Immunol; 1992 Sep; 12(5):353-61. PubMed ID: 1430106
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.
    Jonsson MK; Sundlisæter NP; Nordal HH; Hammer HB; Aga AB; Olsen IC; Brokstad KA; van der Heijde D; Kvien TK; Fevang BS; Lillegraven S; Haavardsholm EA
    Ann Rheum Dis; 2017 Dec; 76(12):2031-2037. PubMed ID: 28814431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The anti-rheumatic effect of multiple synovectomy in patients with refractory rheumatoid arthritis.
    Nakamura H; Nagashima M; Ishigami S; Wauke K; Yoshino S
    Int Orthop; 2000; 24(5):242-5. PubMed ID: 11153450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
    Rubbert-Roth A; Enejosa J; Pangan AL; Haraoui B; Rischmueller M; Khan N; Zhang Y; Martin N; Xavier RM
    N Engl J Med; 2020 Oct; 383(16):1511-1521. PubMed ID: 33053283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protein biochip array technology to monitor rituximab in rheumatoid arthritis.
    Fabre S; Guisset C; Tatem L; Dossat N; Dupuy AM; Cohen JD; Cristol JP; Daures JP; Jorgensen C
    Clin Exp Immunol; 2009 Mar; 155(3):395-402. PubMed ID: 19220830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the efficacy and safety indicators of DMARDs for rheumatoid arthritis: A network meta-analysis.
    Wang Z; Huang M; Yu B; Huang Y; Zheng S; Yang X; Ning H
    Medicine (Baltimore); 2021 Jul; 100(29):e26524. PubMed ID: 34398007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MIF and TNFα serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study.
    Brennan-Bourdon LM; De la Cruz-Mosso U; Reyes-Castillo Z; Martínez-Bonilla GE; Ramírez-Dueñas MG; Islas-Carbajal MC; Rincón-Sánchez AR; Salazar-Páramo M; Muñoz-Valle JF
    Immunopharmacol Immunotoxicol; 2015 Apr; 37(2):207-13. PubMed ID: 25721154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
    Wells G; Becker JC; Teng J; Dougados M; Schiff M; Smolen J; Aletaha D; van Riel PL
    Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.
    Fabre S; Dupuy AM; Dossat N; Guisset C; Cohen JD; Cristol JP; Daures JP; Jorgensen C
    Clin Exp Immunol; 2008 Aug; 153(2):188-95. PubMed ID: 18549443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis.
    Dessein PH; Joffe BI
    Clin Exp Rheumatol; 2006; 24(2):161-7. PubMed ID: 16762151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
    Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
    Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
    Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
    Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glucocorticoid-sparing effect of first-year anti-TNFα treatment in rheumatoid arthritis (CORPUS Cohort).
    Duquenne C; Wendling D; Sibilia J; Job-Deslandre C; Guillevin L; Benichou J; Flipo RM; Guillemin F; Saraux A
    Clin Exp Rheumatol; 2017; 35(4):638-646. PubMed ID: 28516872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort.
    Le Loët X; Brazier M; Mejjad O; Boumier P; Daragon A; Gayet A; Pouplin S; Tron F; Zarnitsky C; Vittecoq O; Menard JF; Fardellone P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1739-47. PubMed ID: 20740612
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of antirheumatic drugs on circulating immune complexes in rheumatoid arthritis.
    Forster PJ; McConkey B
    Q J Med; 1986 Jan; 58(225):29-42. PubMed ID: 2871585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.